Am J Med Genet B Neuropsychiatr Genet

1. SERRETTI A, Souery D, Kasper S, Zohar J, et al
   Schizophrenia Genetics Modulates Clinical Depressive Features.
   Am J Med Genet B Neuropsychiatr Genet. 2025 Oct 20. doi: 10.1002/ajmg.b.33066.
   

   >> Share

   
   

   
   Biol Psychiatry

2. HOWES OD, Vano LJ, Petty AE, Rutigliano G, et al
   The trace amine-associated receptor 1 regulates presynaptic dopamine function: evidence from preclinical studies and a phase 1b trial in patients with schizophrenia.
   Biol Psychiatry. 2025 Oct 21:S0006-3223(25)01533.
   

   >> Share

   
   
3. MEMETOGLU O, Du F, Chouinard VA, Ongur D, et al
   Reductive Stress and Dysregulated Energy Metabolism in Schizophrenia: Mechanisms and Therapeutic Targets.
   Biol Psychiatry. 2025 Oct 16:S0006-3223(25)01528.
   

   >> Share

   
   

   
   Can J Psychiatry

4. SKIBA RM, Chinchani AM, Menon M, Lepage M, et al
   A multisite study of the overlap between symptoms and cognition in schizophrenia: Une etude multicentrique sur le chevauchement entre les symptomes et les troubles cognitifs chez les personnes atteintes de schizophrenie.
   Can J Psychiatry. 2025 Oct 22:7067437251387565. doi: 10.1177/07067437251387565.
   

   >> Share

   
   

   
   J Clin Psychiatry

5. FAN X, Freudenreich O, Jarskog LF, McEvoy J, et al
   Brexpiprazole for the Treatment of Co-occurring Schizophrenia and Substance Use Disorder: A Multisite, Randomized, Controlled Trial.
   J Clin Psychiatry. 2025;86:25m15786.
   

   >> Share

   
   

   
   Mol Psychiatry

6. LIU S, Agartz I, Allen P, Amminger GP, et al
   Structural covariance network topology in individuals at clinical high risk for psychosis: the ENIGMA-CHR Study.
   Mol Psychiatry. 2025 Oct 22. doi: 10.1038/s41380-025-03304.
   

   >> Share

   
   

   
   Psychiatry Res

7. MUELLER N, Mulfarth R, Seuffert S, Dannlowski U, et al
   Figurative language production in schizophrenia, bipolar disorder, and depression.
   Psychiatry Res. 2025;354:116772.
   

   >> Share

   
   

   
   Schizophr Res

8. XAVIER G, Ota V, Kajitani GS, Mauer JH, et al
   Dysregulation of miR-335-5p, miR-30d-5p, and miR-744-5p in extracellular vesicles from first-episode psychosis patients: Implications for biomarker discovery.
   Schizophr Res. 2025;286:74-81.
   

   >> Share

   
   
9. FABRIS D, Andrade LM, Freitas IS, Gomes FV, et al
   Cannabidiol attenuates behavioral and electrophysiological changes in the MAM model of schizophrenia in male and female rats.
   Schizophr Res. 2025;286:63-73.
   

   >> Share

   
   
10. CAMON E, Masier S, Mota NB, D'Agostino A, et al
    Machine learning and graph-based connectivity metrics identify language disruption in psychosis: Novel insights from dream reports in an Italian cohort.
    Schizophr Res. 2025;286:55-62.
    

    >> Share

    
    
11. JI T, Yu B, Ma R
    Cerebellar-cortical dysfunction and schizophrenia: Advances in neurocognition and therapeutic strategies.
    Schizophr Res. 2025;286:37-46.
    

    >> Share

    
    
12. KWOK SYCL, Li Y, Chu MH, Singh H, et al
    The effectiveness of enhanced WELLFOCUS positive psychotherapy for people with schizophrenia: A randomised controlled trial in halfway houses in Hong Kong.
    Schizophr Res. 2025;286:26-36.
    

    >> Share

    
    
13. TABATA K, Toriumi K, Suzuki K, Takagi H, et al
    Schizophrenia with hypozincemia: Clinical features and symptom severity.
    Schizophr Res. 2025;286:9-15.
    

    >> Share

    
    
14. LUTHER L, Mathis RF, Keller WR, Buchanan RW, et al
    Aberrant visual attention is associated with social judgements of attractiveness and negative symptoms in schizophrenia.
    Schizophr Res. 2025;286:1-8.
    

    >> Share

    
    
15. DENAROSO GE, Liu J, Ered A, Woodward ND, et al
    Nonlinear associations between reported childhood trauma and cognitive impairment in schizophrenia spectrum disorders.
    Schizophr Res. 2025;285:360-368.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share